Japan's UMN surges on US approval of Flublok
This article was originally published in Scrip
Executive Summary
Shares in the recently listed Japanese venture UMN Pharma went limit-up in Tokyo on 17 January following the US approval the previous day of UMN's technology licensor Protein Sciences' recombinant flu vaccine Flublok (scripintelligence.com, 17 January 2013).